Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
Featured AnalysisThe ICH Q11 Three-Part Justification — What FDA and EMA Require for Starting Material Designation and Where Programs Fall ShortXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Genzyme’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
Featured AnalysisFDA Inspection Front Room Protocol — What to Say and What Not ToXGene analysis · Aug 22, 2026Read Article →
Latest Warning LetterInside Ranbaxy’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptWARNING LETTER · Aug 22, 2026Open Regulatory Record →
CMC AnalysisSalt and Co-Crystal Selection: CMC Documentation of Pharmaceutical Form Decisions in Module 3XGene analysis · Aug 22, 2026Explore CMC Analysis →
FDA 483 SignalInside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will AcceptFDA 483 · Aug 22, 2026Open Regulatory Record →
Featured AnalysisPolymorphism in Drug Substances: The ICH Q6A Decision Tree, Solid-State Characterization, and Process-Induced Form Conversion RiskXGene analysis · Aug 22, 2026Read Article →
Regulatory SignalZhejiang Gaorong Cosmetic Co., Ltd. Added to Import Alert 66-40: The CGMP Pattern Behind the Detention and What Every Quality Director Managing Cross-Category Drug, Biologic, and Supplement Supply Chains Must KnowIMPORT ALERT · Aug 22, 2026Open Regulatory Record →
Sterile / Aseptic XGene CMC Intelligence Sterile / Aseptic Sterility assurance, aseptic operations, recalls and contamination control. Featured analysis Excelvision Warning Letter Catalent Indiana LLC FDA 483: 8 Observations at Bloomington, Indiana and the Aseptic/Sterile Manufacturing Pattern Every Sterile Injectable Quality Leader Should Assess CareFusion 213, LLC (BD) Recall Class I — ChloraPrep Sterile Antiseptic Applicators — June 25, 2026 Current regulatory intelligence Excelvision Warning Letter: Sterility Assurance Failure and the CMC Pattern Every Sterile Products Quality Director Must Recognize Wizcure Pharmaa Warning Letter: Data Integrity and the CMC Pattern Every Sterile OTC Drug Quality Director Must Recognize CareFusion 213, LLC (BD) Class I Recall — ChloraPrep Sterile Antiseptic Applicators: The Sterile Manufacturing System Failure Behind the Recall and What Every Aseptic Processing Director Must Address Inside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept Catalent Indiana LLC FDA 483: 8 Observations at Bloomington, Indiana and the Aseptic/Sterile Manufacturing Pattern Every Sterile Injectable Quality Leader Should Assess Request an Annex 1 / Sterility Assurance Assessment
Catalent Indiana LLC FDA 483: 8 Observations at Bloomington, Indiana and the Aseptic/Sterile Manufacturing Pattern Every Sterile Injectable Quality Leader Should Assess
Excelvision Warning Letter: Sterility Assurance Failure and the CMC Pattern Every Sterile Products Quality Director Must Recognize
Wizcure Pharmaa Warning Letter: Data Integrity and the CMC Pattern Every Sterile OTC Drug Quality Director Must Recognize
CareFusion 213, LLC (BD) Class I Recall — ChloraPrep Sterile Antiseptic Applicators: The Sterile Manufacturing System Failure Behind the Recall and What Every Aseptic Processing Director Must Address
Inside PharMEDium’s Consent Decree: What the Terms Reveal About FDA’s Enforcement Standard and the Manufacturing System It Will Accept
Catalent Indiana LLC FDA 483: 8 Observations at Bloomington, Indiana and the Aseptic/Sterile Manufacturing Pattern Every Sterile Injectable Quality Leader Should Assess
